Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
85.6
Signal Score
✓ FDA Inspections (3)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Pharmaron Biologics
- Signal Score
- 85.6/100 (as of 2026-04-29)
- Quality Compliance
- 100.0/100 — Bonus: 3 consecutive NAI inspections
- Headquarters
- San Diego, CA · Shaoxing, CN
- Modalities
- AAV, Lentiviral, Plasmid
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Pharmaron Biologics
Chinese CRO/CDMO with US CGT operations.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Bonus: 3 consecutive NAI inspections
Source: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections3 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-07-17)
Bonus: 3 consecutive NAI inspections
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
83.0
Publicly traded — financial transparency
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity
63.0
2 manufacturing sites
Sites: San Diego, CA, Shaoxing, China
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
2 manufacturing sites
Pharmaron Biologics FDA Inspection History
2025-07
2025-01
2024-09
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-07-17 | Coventry, Rhode Island | Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2025-01-17 | Exton, Pennsylvania | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
| 2024-09-27 | Exton, Pennsylvania | Bioresearch Monitoring | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Jul 04, 2026
Frequently Asked Questions About Pharmaron Biologics
How many FDA inspections does Pharmaron Biologics have on record?
CDMO Signal tracks 3 FDA inspections for Pharmaron Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has Pharmaron Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Pharmaron Biologics.
What is Pharmaron Biologics's CDMO Signal Score?
Pharmaron Biologics has a Signal Score of 86/100, based on quality, operations, financial stability, and capacity data.
Evaluating Pharmaron Biologics for a manufacturing program?
Use the free AI matchmaker to compare Pharmaron Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
uBriGene Biosciences
Shanghai, CN · Boston, MA
Signal Score: 60.5
AAV, Lentiviral, Plasmid
Ascend Advanced Therapies
Philadelphia, PA
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral